Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-1966
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MK-1966 is an investigational anti-interleukin-10 (anti-IL-10) immunomodulator developed by Merck. It is a monoclonal antibody designed to neutralize the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), thereby reducing immune suppression in the tumor microenvironment and potentially enhancing antitumor immune responses. The drug was primarily investigated for oncology indications, aiming to modulate immune responses against cancer cells. Clinical development reached Phase 1, but trials were terminated before completion[1][2][3][4][5].
- Other names
- IL-10 immunomodulator MK-1966IL10 immunomodulator MK-1966IL 10 immunomodulator MK-1966
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on MK-1966.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-1966.